FDA approves eNeura's brain-stimulation device to treat migraines

eNeura's Cerena TMS--Courtesy of eNeura

California's eNeura won FDA approval for its portable migraine-fighting device, heading to the U.S. market with a transcranial magnetic stimulation tech that can relieve pain in some of the most extreme cases.

The device, called Cerena TMS, is designed to treat migraines that are preceded by a sensory disturbance, using a magnetic pulse to stimulate the brain's occipital cortex and alleviate pain. In a pivotal trial on 201 patients, nearly 38% of migraine sufferers who used Cerena TMS were pain-free two hours after onset compared to about 17% in the control group, and nearly 34% of those in the treatment arm stayed that way after 24 hours, besting the 10% rate of the control segment, the FDA said.

Roughly 10% of people suffer from migraines, according to the agency, and one-third experience sensory disruptions beforehand. Cerena TMS is already CE marked and commercially available overseas, and now, with the FDA's blessing, eNeura can hit the ground running with a U.S. launch.

ENeura is the first to win FDA approval for a migraine-treating TMS application, but the company is hardly alone in finding a therapeutic angle in what was once only an imaging technology. Israel's Brainsway won FDA approval in January for Deep TMS, using a similar mechanism to treat depression. Neuronetics has a CE-marked device that works the same way, and Cervel Neurotech raised $14.1 million this year to develop a TMS system for chronic pain.

- read the release

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.